Angion Biomedica Corp

NASDAQ:ANGN

14.40

+0.08 (+0.56%)

Market Cap (Intraday)	424.58M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.89 Million
Adjusted EPS	-$0.62

See more estimates

10-Day MA	N/A
50-Day MA	N/A
200-Day MA	N/A

See more pivots

Angion Biomedica Corp Stock, NASDAQ:ANGN

51 Charles Lindbergh Boulevard, Suite 1200, Uniondale, New York 11553

United States of America

Phone: +1.415.655.4899

Number of Employees: 53

http://www.angion.com

Description

Angion Biomedica Corp. operates as a biopharmaceutical company. It focuses on the discovery and development of novel therapeutic agents to address acute organ injuries and fibrotic diseases. Its product pipeline includes ANG-3777, ANG-3070, ROCK2 Inhibitor and CYP11B2 Inhibitors. The company was founded by Itzhak D. Goldberg on April 06, 1998 and is headquartered in Uniondale, NY.